# Agilent (A) Q2 FY2026 earnings

Results filed 2026-05-27 for the quarter ended 2026-04-30. Source page: https://earnings.opennash.com/companies/a/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1090872/000109087226000052/0001090872-26-000052-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Agilent launched its 9500 ICP-MS platform and said replacement-cycle demand and its Ignite Operating System drove broad-based strength across pharma, diagnostics, chemicals and forensics.

Demand was broad. Instruments grew at a high-single-digit rate, led by low-double-digit growth in liquid chromatography and LC/MS as customers replaced older equipment. Pharma had its fifth straight quarter of mid-single to low-double-digit growth, Cancer Diagnostics grew double digits, and semiconductor demand lifted chemicals. Forensics won share and a TSA airport security contract. Agilent also launched the 9500 ICP-MS platform and announced the Biocare acquisition in March.
Management is steering toward replacement cycles, innovation and the Ignite Operating System, which it credits for pricing gains and efficiencies. It raised its full-year outlook and expects momentum to continue into the third quarter. The tensions are in academia and government, where funding still weighs on instrument spending. China is also a tough comparison against last year's pre-tariff consumables stocking, and funding delays in China and India hurt Food.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $1.83 billion | up 10.0% reported and 6.3% core from a year ago | GAAP |
| GAAP net income | $339 million |  | GAAP |
| GAAP diluted EPS | $1.20 | up 60% from a year ago | GAAP |
| Non-GAAP EPS | $1.49 | up 14% from a year ago | non-GAAP |
| Non-GAAP operating margin | 26.4% | expanded by 130 basis points year-over-year | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Life Sciences and Diagnostics Markets Group | $732 million | growth of 12% reported and 9% core |
| Agilent CrossLab Group | $759 million | growth of 6% reported and 2% core |
| Applied Markets Group | $344 million | growth of 14% reported and 11% core |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Q3 revenue | fiscal third-quarter 2026 | $1.83 billion to $1.85 billion |
| Q3 non-GAAP EPS | fiscal third-quarter 2026 | $1.48 to $1.50 |
| FY26 revenue | fiscal year 2026 | $7.39 billion to $7.49 billion |
| FY26 non-GAAP EPS | fiscal year 2026 | $6.00 to $6.10 |

## Key takeaways

1. **Replacement cycle is driving instrument demand** Liquid chromatography and LC/MS grew at a low-double-digit rate in the Life Sciences and Diagnostics Markets Group, and Gas Chromatography grew at a low double-digit rate in Applied Markets. Management cites tech refresh and replacement-cycle momentum as a core growth driver.
2. **Agilent launched the 9500 ICP-MS platform** The CEO pointed to the new 9500 ICP-MS as proof that Agilent can anticipate customer needs and improve laboratory productivity. New launches were also set to be shown at ASMS the following week.
3. **Cancer Diagnostics and Omnis drive clinical growth** Diagnostics and Clinical grew 11%, driven by expanding Cancer Diagnostics offerings and traction for the Omnis family. Companion diagnostics services also grew at a double-digit rate.
4. **Ignite is delivering pricing gains and efficiencies** Agilent says its Ignite Operating System drives pricing gains and operating efficiencies. A strategic pricing capability delivered roughly 200 basis points of pricing in the quarter.
5. **Academia, China and Food remain soft spots** Academia and Government fell 5% on muted research funding, and Food fell 3% on funding delays in China and India. Services and consumables outside China grew at a mid-single-digit rate, but a tough comparison on pre-tariff stocking held China back.

## Questions

**What new product did Agilent highlight this quarter?** The new 9500 ICP-MS platform. The CEO said it shows Agilent can anticipate customer needs and improve laboratory productivity. More launches were slated for ASMS the following week.
**Where is Agilent's demand strongest?** Pharma (including biotech), Diagnostics and Clinical, Chemicals and Advanced Materials, and Environmental and Forensics all grew. Semiconductor demand, Cancer Diagnostics and a TSA airport security contract were cited as drivers.
**What role does the replacement cycle play?** Management says replacement-cycle and tech-refresh momentum is lifting instruments, including low-double-digit growth in LC and LC/MS and in GC.
**Which areas are weak or uncertain?** Academia and Government fell 5% on muted funding. Food fell 3% on funding delays in China and India, and China faced a tough comparison against last year's pre-tariff consumables stocking.
**Did Agilent make acquisitions or change its outlook?** It announced the Biocare acquisition in March. It also raised its fiscal 2026 revenue growth, margin expansion and EPS guidance, citing increased confidence in execution.

## Slides and investor documents

- [Quarterly Results Presentation](https://s24.q4cdn.com/305549747/files/doc_earnings/2026/q2/presentation/Q226-Results-Presentation.pdf) (Slide deck)
- [Prepared Remarks](https://s24.q4cdn.com/305549747/files/doc_earnings/2026/q2/transcript/Q2-26-Prepared-Remarks-Final.pdf) (CFO commentary)
- [Financial Information](https://s24.q4cdn.com/305549747/files/doc_earnings/2026/q2/supplemental-info/Q2-26-Financial-Information-Final.xls) (Document)
- [Financial Information](https://s24.q4cdn.com/305549747/files/doc_earnings/2026/q2/supplemental-info/Q2-26-Financial-Information-Final.pdf) (Document)

